Insider · CIK 0001680739

Baynes Roy D.

Reports to the SEC for 6 companies · SAN DIEGO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001680739

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-08-14	AARDAardvark Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+45K sh	—	—	44,964
2026-06-26	NTRANatera, Inc.A Award	Director	AAward	+75 sh	—	—	20,158
2026-06-26	NTRANatera, Inc.A Award	Director	AAward	+1,571 sh	—	—	20,083
2026-06-12	TVTXTravere Therapeutics, Inc. · Stock option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−4,500 sh	—	—	0
2026-06-12	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+4,500 sh	$21.38	+$96.2K	46,000
2026-06-12	TVTXTravere Therapeutics, Inc.S Sale	Director	SSale	−4,500 sh	$50.00	−$225K	41,500
2026-05-19	TVTXTravere Therapeutics, Inc. · Stock option (right to buy)A Award	Director	AAward	+12K sh	—	—	12,000
2026-05-19	TVTXTravere Therapeutics, Inc.A Award	Director	AAward	+4,000 sh	—	—	41,500
2026-05-15	NRIXNurix Therapeutics, Inc. · Director Stock Option (right to buy)A Award	Director	AAward	+31.3K sh	—	—	31,250
2026-05-05	TVTXTravere Therapeutics, Inc.S Sale	Director	SSale	−4,500 sh	$46.65	−$210K	37,500
2026-05-05	TVTXTravere Therapeutics, Inc. · Stock option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−4,500 sh	—	—	0
2026-05-05	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+4,500 sh	$18.27	+$82.2K	42,000
2026-05-01	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+9,750 sh	$6.82	+$66.5K	47,250
2026-05-01	TVTXTravere Therapeutics, Inc.S Sale	Director	SSale	−9,750 sh	$44.22	−$431K	37,500
2026-05-01	TVTXTravere Therapeutics, Inc. · Stock option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−9,750 sh	—	—	9,750
2026-04-24	NTRANatera, Inc.A Award	Director	AAward	+83 sh	—	—	18,512
2026-04-14	TVTXTravere Therapeutics, Inc. · Stock option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−8,000 sh	—	—	0
2026-04-14	TVTXTravere Therapeutics, Inc. · Stock option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−4,500 sh	—	—	4,500
2026-04-14	TVTXTravere Therapeutics, Inc. · Stock option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−4,500 sh	—	—	4,500
2026-04-14	TVTXTravere Therapeutics, Inc. · Stock option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−6,750 sh	—	—	6,750
2026-04-14	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+9,000 sh	$15.43	+$139K	54,500
2026-04-14	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+8,000 sh	$17.94	+$144K	45,500
2026-04-14	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+4,500 sh	$21.38	+$96.2K	63,500
2026-04-14	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+4,500 sh	$18.27	+$82.2K	59,000
2026-04-14	TVTXTravere Therapeutics, Inc.S Sale	Director	SSale	−26K sh	$41.07	−$1.07M	44,250
2026-04-14	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+6,750 sh	$17.11	+$115K	70,250
2026-04-14	TVTXTravere Therapeutics, Inc.S Sale	Director	SSale	−6,750 sh	$42.12	−$284K	37,500
2026-04-14	TVTXTravere Therapeutics, Inc. · Stock option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−9,000 sh	—	—	0
2026-04-06	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+10K sh	$26.52	+$265K	47,500
2026-04-06	TVTXTravere Therapeutics, Inc.S Sale	Director	SSale	−10K sh	$33.00	−$330K	37,500
2026-04-06	TVTXTravere Therapeutics, Inc. · Stock option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−10K sh	—	—	0
2026-03-02	EIKNEikon Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Medical Officer	AAward	+134K sh	—	—	134,088
2026-01-30	NTRANatera, Inc.A Award	Director	AAward	+70 sh	—	—	18,429
2025-11-20	NTRANatera, Inc. · Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−600 sh	—	—	0
2025-11-20	NTRANatera, Inc. · Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−7,068 sh	—	—	0
2025-11-20	NTRANatera, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+600 sh	$40.93	+$24.6K	18,959
2025-11-20	NTRANatera, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+7,068 sh	$41.19	+$291K	26,027
2025-11-20	NTRANatera, Inc.S Sale	Director	SSale	−900 sh	$221.81	−$200K	23,943
2025-11-20	NTRANatera, Inc.S Sale	Director	SSale	−1,184 sh	$220.14	−$261K	24,843
2025-11-20	NTRANatera, Inc.S Sale	Director	SSale	−1,800 sh	$222.90	−$401K	22,143
2025-11-20	NTRANatera, Inc.S Sale	Director	SSale	−1,900 sh	$223.90	−$425K	20,243
2025-11-20	NTRANatera, Inc.S Sale	Director	SSale	−1,884 sh	$224.89	−$424K	18,359
2025-11-19	NTRANatera, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+5,112 sh	$40.93	+$209K	23,471
2025-11-19	NTRANatera, Inc.S Sale	Director	SSale	−1,250 sh	$213.47	−$267K	22,221
2025-11-19	NTRANatera, Inc.S Sale	Director	SSale	−1,727 sh	$214.79	−$371K	20,494
2025-11-19	NTRANatera, Inc.S Sale	Director	SSale	−2,135 sh	$216.07	−$461K	18,359
2025-11-19	NTRANatera, Inc. · Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−5,112 sh	—	—	600
2025-10-31	NTRANatera, Inc.A Award	Director	AAward	+93 sh	—	—	18,359
2025-07-25	NTRANatera, Inc.A Award	Director	AAward	+108 sh	—	—	18,266
2025-06-27	NTRANatera, Inc.A Award	Director	AAward	+2,143 sh	—	—	18,158

Recent filings

Accepted (ET)
Aug 214
Baynes Roy D.0001193125-26-361482
SEC(opens sec.gov)
Jun 304
Baynes Roy D.0001680739-26-000015
SEC(opens sec.gov)
Jun 164
Baynes Roy D.0001680739-26-000014
SEC(opens sec.gov)
May 214
Baynes Roy D.0001680739-26-000012
SEC(opens sec.gov)
May 154
Baynes Roy D.0001680739-26-000010
SEC(opens sec.gov)
May 64
Baynes Roy D.0001680739-26-000008
SEC(opens sec.gov)
May 44
Baynes Roy D.0001680739-26-000007
SEC(opens sec.gov)
Apr 284
Baynes Roy D.0001680739-26-000006
SEC(opens sec.gov)
Apr 164
Baynes Roy D.0001680739-26-000005
SEC(opens sec.gov)

Companies

Address

C/O AARDVARK THERAPEUTICS, INC. 4370 LA JOLLA VILLAGE DRIVE, SUITE 1050

SAN DIEGO, CA, 92122